NCT05243017View on ClinicalTrials.gov

Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 7, 2021

Primary Completion Date

March 31, 2029

Study Completion Date

October 7, 2029

Conditions
Huntington Disease
Interventions
GENETIC

intra-striatal rAAV5-miHTT

One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain

Trial Locations (4)

Unknown

Instytut Psychiatrii i Neurologii, Warsaw

Interventional Neuro Center, Warsaw

Cardiff University, Cardiff

National Hospital for Neurology & Neurosurgery, London

All Listed Sponsors
lead

UniQure Biopharma B.V.

INDUSTRY